Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ChiCTR-SIC-17011273
ChiCTR-SIC-17011273Active, not recruitingPhase 1

中国意义未明单克隆免疫球蛋白增多症患病率的调查

自筹1 site in 1 country1,525 target enrollmentStarted: May 16, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
1,525
Locations
1
Primary Endpoint
骨髓瘤相关损害
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

初步筛查中国人群中 MGUS 的患病率，对阳性患者随访疾病进展的真实状况

Study Design

Study Type
筛查
Primary Purpose
横断面

Eligibility Criteria

Ages
40 to 100 (—)
Sex
All

Inclusion Criteria

  • •大于等于 40 岁，中国籍贯，住院病人

Exclusion Criteria

  • •明确诊断为非“MGUS”的浆细胞病病人

Arms & Interventions

5

Outcomes

Primary Outcomes

骨髓瘤相关损害

Secondary Outcomes

  • 年龄、性别等

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
请整合上传所有伦理批件。 中国多发性硬化患者脑脊液免疫球蛋白 G 寡克隆带检测（“CNS-OCB”）的临床研究多发性硬化
ChiCTR2000040363研究者自费
Unknown
Not Applicable
全国多中心孕期人群常见单基因病携带者筛查单基因遗传病
ChiCTR1800016054深圳华大基因股份有限公司45
Unknown
Not Applicable
静脉注射人免疫球蛋白治疗多灶性运动神经病的探索性临床试验
ChiCTR2500106815元羿生物医药科技（上海）有限公司
Unknown
Not Applicable
中国城镇人群自身免疫性大疱病的发病率与患病率调查
ChiCTR2300069065北京大学医学部-皮尔法伯集团共建“国家皮肤与免疫疾病临床医学研究中心-皮尔法伯集团-皮肤健康促进协同创新实验室”项目
Not yet recruiting
Not Applicable
Longitudinal study on dengue and Zika infections in Kerala
CTRI/2025/07/090539Wellcome Trust28,000